Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06705504 · ClinicalTrials.gov registry record
A Real-world Study of Effectiveness and Safety in HR+/HER2- Breast Cancer Patients Treated With Ribociclib or Alpelisib
A clinical trial, sponsored by Novartis.
- Completed
- Registry status
- 435
- Enrollment target
NCT06705504 is a clinical trial that has completed, run by Novartis. The registered enrollment target is 435 participants.
The verdict
NCT06705504 has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- 435 participants
- Enrollment target
Study Summary
This study was a multinational and multicenter cohort study of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer (aBC/mBC) treated with ribociclib or alpelisib between the period of 01 January 2018 and 30 September 2021. Patients who were receiving active treatment for malignancies other than BC or participating in a clinical trial were excluded. This study was conducted retrospectively with secondary use of data.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 435 participants |
| Start Date | 2021-06-11 |
| Est. Completion | 2023-11-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06705504
The ClinicalTrials.gov registry entry for NCT06705504 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 435 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT06705504 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06705504 about?
NCT06705504 is a clinical study titled "A Real-world Study of Effectiveness and Safety in HR+/HER2- Breast Cancer Patients Treated With Ribociclib or Alpelisib". This study was a multinational and multicenter cohort study of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer (aBC/mBC) treated with ribociclib or alpelisib between the period of 01 January 2018 and 30 Septem...
What is the current status of trial NCT06705504?
This trial is currently completed. The enrollment target is 435 participants. The study started on 2021-06-11. Estimated completion is 2023-11-30.
Who is sponsoring clinical trial NCT06705504?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.